Steady Growth at J&J Reinforces Wide Moat, But Shares Overpriced
April 19, 2016 at 12:00 PM EDT
An anticipated slowdown in pharma giant’s drug business gives us some pause on the firm’s current valuation, but its long-term competitive advantages are intact.
